IDEAS home Printed from https://ideas.repec.org/a/nat/nature/v534y2016i7607d10.1038_nature18288.html
   My bibliography  Save this article

Dual targeting of p53 and c-MYC selectively eliminates leukaemic stem cells

Author

Listed:
  • Sheela A. Abraham

    (Paul O’Gorman Leukaemia Research Centre, Institute of Cancer Sciences, University of Glasgow, Gartnavel General Hospital)

  • Lisa E. M. Hopcroft

    (Paul O’Gorman Leukaemia Research Centre, Institute of Cancer Sciences, University of Glasgow, Gartnavel General Hospital)

  • Emma Carrick

    (Stem Cell and Leukaemia Proteomics laboratory, University of Manchester
    Manchester Precision Medicine Institute, University of Manchester)

  • Mark E. Drotar

    (Paul O’Gorman Leukaemia Research Centre, Institute of Cancer Sciences, University of Glasgow, Gartnavel General Hospital)

  • Karen Dunn

    (Paul O’Gorman Leukaemia Research Centre, Institute of Cancer Sciences, University of Glasgow, Gartnavel General Hospital)

  • Andrew J. K. Williamson

    (Stem Cell and Leukaemia Proteomics laboratory, University of Manchester
    Manchester Precision Medicine Institute, University of Manchester)

  • Koorosh Korfi

    (Paul O’Gorman Leukaemia Research Centre, Institute of Cancer Sciences, University of Glasgow, Gartnavel General Hospital
    Institute of Cancer Sciences, University of Glasgow)

  • Pablo Baquero

    (Institute of Cancer Sciences, University of Glasgow)

  • Laura E. Park

    (Paul O’Gorman Leukaemia Research Centre, Institute of Cancer Sciences, University of Glasgow, Gartnavel General Hospital)

  • Mary T. Scott

    (Paul O’Gorman Leukaemia Research Centre, Institute of Cancer Sciences, University of Glasgow, Gartnavel General Hospital)

  • Francesca Pellicano

    (Paul O’Gorman Leukaemia Research Centre, Institute of Cancer Sciences, University of Glasgow, Gartnavel General Hospital)

  • Andrew Pierce

    (Stem Cell and Leukaemia Proteomics laboratory, University of Manchester
    Manchester Precision Medicine Institute, University of Manchester)

  • Mhairi Copland

    (Paul O’Gorman Leukaemia Research Centre, Institute of Cancer Sciences, University of Glasgow, Gartnavel General Hospital)

  • Craig Nourse

    (Institute of Cancer Sciences, University of Glasgow)

  • Sean M. Grimmond

    (University of Melbourne Centre for Cancer Research, University of Melbourne)

  • David Vetrie

    (Institute of Cancer Sciences, University of Glasgow)

  • Anthony D. Whetton

    (Stem Cell and Leukaemia Proteomics laboratory, University of Manchester
    Manchester Precision Medicine Institute, University of Manchester
    Stoller Biomarker Discovery Centre, University of Manchester)

  • Tessa L. Holyoake

    (Paul O’Gorman Leukaemia Research Centre, Institute of Cancer Sciences, University of Glasgow, Gartnavel General Hospital)

Abstract

Chronic myeloid leukaemia (CML) arises after transformation of a haemopoietic stem cell (HSC) by the protein-tyrosine kinase BCR–ABL. Direct inhibition of BCR–ABL kinase has revolutionized disease management, but fails to eradicate leukaemic stem cells (LSCs), which maintain CML. LSCs are independent of BCR–ABL for survival, providing a rationale for identifying and targeting kinase-independent pathways. Here we show—using proteomics, transcriptomics and network analyses—that in human LSCs, aberrantly expressed proteins, in both imatinib-responder and non-responder patients, are modulated in concert with p53 (also known as TP53) and c-MYC regulation. Perturbation of both p53 and c-MYC, and not BCR–ABL itself, leads to synergistic cell kill, differentiation, and near elimination of transplantable human LSCs in mice, while sparing normal HSCs. This unbiased systems approach targeting connected nodes exemplifies a novel precision medicine strategy providing evidence that LSCs can be eradicated.

Suggested Citation

  • Sheela A. Abraham & Lisa E. M. Hopcroft & Emma Carrick & Mark E. Drotar & Karen Dunn & Andrew J. K. Williamson & Koorosh Korfi & Pablo Baquero & Laura E. Park & Mary T. Scott & Francesca Pellicano & A, 2016. "Dual targeting of p53 and c-MYC selectively eliminates leukaemic stem cells," Nature, Nature, vol. 534(7607), pages 341-346, June.
    • Handle: RePEc:nat:nature:v:534:y:2016:i:7607:d:10.1038_nature18288
    DOI: 10.1038/nature18288
    as

    Download full text from publisher

    File URL: https://www.nature.com/articles/nature18288
    File Function: Abstract
    Download Restriction: Access to the full text of the articles in this series is restricted.
    File URL: https://libkey.io/10.1038/nature18288?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Kevin M. Rattigan & Zuzana Brabcova & Daniele Sarnello & Martha M. Zarou & Kiron Roy & Ryan Kwan & Lucie Beauchamp & Amy Dawson & Angela Ianniciello & Ahmed Khalaf & Eric R. Kalkman & Mary T. Scott & , 2023. "Pyruvate anaplerosis is a targetable vulnerability in persistent leukaemic stem cells," Nature Communications, Nature, vol. 14(1), pages 1-17, December.
    2. Yinzhe GE & Mang XIAO, 2019. "Chronic Myeloid Leukemia: How to Overcome the Tyrosine Kinase Inhibitors Resistance," Biomedical Journal of Scientific & Technical Research, Biomedical Research Network+, LLC, vol. 18(2), pages 13389-13393, May.
    3. Mary T. Scott & Wei Liu & Rebecca Mitchell & Cassie J. Clarke & Ross Kinstrie & Felix Warren & Hassan Almasoudi & Thomas Stevens & Karen Dunn & John Pritchard & Mark E. Drotar & Alison M. Michie & Hea, 2024. "Activating p53 abolishes self-renewal of quiescent leukaemic stem cells in residual CML disease," Nature Communications, Nature, vol. 15(1), pages 1-15, December.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:nature:v:534:y:2016:i:7607:d:10.1038_nature18288. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.